Collegium nominates Michael Donovan for board; director John Fallon to retire

COLLEGIUM PHARMACEUTICAL, INC

Michael Donovan, 60, audit partner at EY since 2002, nominated to stand for election at 2026 annual meeting.
John Fallon, M.D., will not stand for re-election and will retire from the board effective as of the annual meeting.
Dr. Fallon served as director since 2016; his retirement is part of board refreshment and succession planning, not due to any disagreement.
Mr. Donovan brings financial expertise from 36 years of experience in life sciences audits and transactions (IPOs, M&A, collaborations).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.